Halozyme Therapeutics (HALO) Total Liabilities (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Total Liabilities of $2.5 billion for Q1 2026, up 43.1% year-over-year from $1.7 billion in Q1 2025, and down 0.95% quarter-over-quarter from $2.5 billion in Q4 2025.
Halozyme Therapeutics (HALO) Total Liabilities (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Total Liabilities for 17 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 43.1% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (up 43.1% YoY), while the FY2025 annual figure was $2.5 billion, up 45.71% from the prior year.
- Total Liabilities slipped to $2.5 billion in Q1 2026 per HALO's latest filing, from $2.5 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $2.5 billion in Q4 2025 and bottomed at $1.2 billion in Q1 2022.
- Historically, Total Liabilities has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 73.65% — and 2023, when it fell 11.86%.
- Halozyme Therapeutics' Total Liabilities stood at $1.7 billion in 2022, then decreased by 1.33% to $1.6 billion in 2023, then advanced by 3.04% to $1.7 billion in 2024, then soared by 45.71% to $2.5 billion in 2025, then fell by 0.95% to $2.5 billion in 2026.
- Business Quant data shows HALO's Total Liabilities at $2.5 billion in Q1 2026, $2.5 billion in Q4 2025, and $1.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 2.43 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.43 Bn |
| Mar 31, 2026 | 2.45 Bn |
| Dec 31, 2025 | 2.48 Bn |
| Sep 30, 2025 | 1.72 Bn |
| Jun 30, 2025 | 1.72 Bn |
| Mar 31, 2025 | 1.71 Bn |
| Dec 31, 2024 | 1.70 Bn |
| Sep 30, 2024 | 1.67 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Mar 31, 2024 | 1.66 Bn |
| Dec 31, 2023 | 1.65 Bn |
| Sep 30, 2023 | 1.64 Bn |
| Jun 30, 2023 | 1.66 Bn |
| Mar 31, 2023 | 1.63 Bn |
| Dec 31, 2022 | 1.67 Bn |
| Sep 30, 2022 | 1.86 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 1.16 Bn |
| Dec 31, 2021 | 1.10 Bn |
| Sep 30, 2021 | 1.19 Bn |